The ESMO Congress 2019 was the global stage for the exchange and debate of translational cancer science of excellence, first announcements of potentially practice changing data, and multidisciplinary must-have conversations set to spur transformative therapies against cancer.
In 2019 we are proud to announce another record – 3,904 submitted abstracts, representing a 16% increase from ESMO Congress 2018.
ESMO-MORA: The Congress programme has been accredited with ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details
The Congress webcasts include all the sessions of the official programme, where speaker permission is granted, and are available on the page dedicated to meeting resources on this is website and OncologyPRO for ESMO members.